Patients with atrial fibrillation taking oral anticoagulants or aspirin to prevent stroke may face an increased risk of heart attack compared to patients taking vitamin k antagonists like warfarin, according to a recent study published in the British Journal of Clinical Pharmacology.
For the study, researchers examined the health data of 30,146 patients diagnosed with atrial fibrillation — an abnormal heart rhythm that causes blood flow issues, which can incite blood clots and subsequent stroke. After adjusting for age, sex, lifestyle and other risk factors, researchers found patients taking aspirin or direct oral anticoagulants like rivaroxaban and dabigatran had double the risk for acute myocardial infarction — heart attack — as patients taking vitamin k antagonists.
Sign up for our FREE E-Weekly for more coverage like this sent to your inbox
"More research should be on-going as use of direct acting oral anticoagulants increases in the population," wrote the study's authors.
The CDC estimates 2.7 to 6.1 million people in the United States have atrial fibriallation. As the U.S. population ages, this number will likely increase.
More articles on quality:
ACA patient safety reforms reduce adverse events by 77k in New Jersey
Stem cell transplant offers first-ever cure for rare blood disorder
Mobile app use decreases in-person follow-ups after surgery